Hemophilia Federation of America and National Hemophilia Foundation continue to follow up on issues arising from Bayer鈥檚 distribution of mislabeled, expired clotting factor and subsequent recall of that product. The most recent set of joint HFA-NHF inquiries to Bayer focused on the short- and long-term medical consequences for affected patients. Bayer today released this response to the joint HFA-NHF letter.
We recognize that Bayer鈥檚 letter does not answer all the questions you may have arising from the product recall. HFA and NHF remind you to please reach out to your physician with any medical concerns.
We also remind you that Bayer has聽provided their call center number if you want to ask them questions, or if you have suffered financial losses due to the recall.聽That number is (888) 842-2937. You may also report adverse medical events directly to the U.S. Food and Drug Administration (www.fda.gov/medwatch, or 1-800-FDA-1088).
HFA鈥檚 and NHF鈥檚 inquiries into the Bayer recall and its ramifications continue. As always, HFA and NHF will keep the bleeding disorders community informed as we learn more.
Please note that HFA and NHF do not recommend, endorse or make any representation about the efficacy, appropriateness or suitability of any specific products, treatments or opinions. If you have any questions or concerns about your medical treatment, including your possible exposure to recalled product, please consult your physician. Events like this one can cause a myriad of emotions.聽Please reach out to a social worker, provider, or trusted source of support.